秋水仙碱与螺内酯在急性心肌梗死中的获益-风险:CLEAR试验预设广义配对比较分析
CLEAR试验的预设探索性分析纳入7062例急性心肌梗死并接受经皮冠状动脉介入治疗的患者,采用广义配对比较(GPC)重新评估低剂量秋水仙碱(0.5 mg/日)和螺内酯(25 mg/日) versus 安慰剂的获益-风险。结果显示,秋水仙碱的首次事件胜率比为0.88(95%CI 0.79-0.98),螺内酯为0.86(95%CI 0.75-0.99),均劣于安慰剂,主要分别由腹泻和男性乳房发育/高钾血症驱动;两种药物均不应常规使用。
要点
- 低剂量秋水仙碱(0.5 mg/日)在心肌梗死后患者中获益-风险劣于安慰剂,胜率比0.88。
- 螺内酯(25 mg/日)同样劣于安慰剂,胜率比0.86,主要因男性乳房发育和高钾血症。
- 两种药物在死亡、再发心梗、卒中、心衰等硬终点上均未见获益。
核心结论
- 在心肌梗死后患者中,低剂量秋水仙碱和螺内酯均显示不利的获益-风险特征,不应常规使用。
研究设计与样本
- CLEAR试验的预设探索性分析,采用2×2析因随机设计,纳入7062例急性心肌梗死72小时内并接受经皮冠状动脉介入治疗的患者。
- 应用时间至首次事件和复发事件广义配对比较(GPC),以胜率比(WR)评估低剂量秋水仙碱(0.5 mg/日)和螺内酯(25 mg/日) versus 安慰剂。
主要发现
- 秋水仙碱的时间至首次事件GPC显示胜率比0.88(95%CI 0.79-0.98;胜率差-2.10%,95%CI -3.84至-0.37),主要因腹泻过多驱动。
- 螺内酯的胜率比0.86(95%CI 0.75-0.99;胜率差-1.46%,95%CI -2.84%至-0.08%),主要归因于男性乳房发育和高钾血症。
- 传统统计方法(Cox、logistic和Andersen-Gill模型)结果与GPC一致。
- 两种干预的高阶疗效终点(死亡、心肌梗死、卒中、心力衰竭)均未见获益。
关键数值与推荐
- 秋水仙碱比较的复合获益-风险终点包括全因死亡、卒中、再发心肌梗死、非计划缺血驱动的血运重建、严重感染或腹泻。
- 螺内酯比较的复合终点包括全因死亡、卒中、心肌梗死、新发或加重的心力衰竭、显著室性心律失常、高钾血症或男性乳房发育/乳房疼痛。
临床怎么用
- 基于CLEAR试验的GPC分析,心肌梗死后患者不应常规使用低剂量秋水仙碱或螺内酯。
- 临床解读复合终点时,GPC可提供直观的获益-风险框架,但本分析结果与常规方法一致,未改变结论。
局限性
- 本分析为预设探索性分析,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Composite outcomes in cardiovascular trials often group events of unequal clinical importance, and conventional analyses may obscure treatment trade-offs. Generalised pairwise comparisons (GPC), expressed as a win ratio (WR), allow for hierarchical ranking of events and incorporation of recurrent outcomes, providing a potentially more intuitive assessment of benefit-risk. METHODS: In a prespecified exploratory analysis of the 2×2 factorial, randomised CLEAR (Colchicine and Spironolactone in Patients with Myocardial Infarction) trial (7062 patients within 72 hours of acute myocardial infarction (MI) and percutaneous coronary intervention), we applied both time-to-first and recurrent-event GPC to reassess low-dose colchicine (0.5 mg daily) and spironolactone (25 mg daily) versus placebo. For the colchicine comparison, the hierarchical benefit-risk outcome included all-cause death, stroke, recurrent MI, unplanned ischaemia-driven revascularisation, serious infection or diarrhoea. For the spironolactone comparison, the outcome included all-cause death, stroke, MI, new or worsening heart failure, significant ventricular arrhythmia, hyperkalaemia or gynaecomastia/gynaecodynia. GPC results were compared with Cox, logistic and Andersen-Gill models. RESULTS: For colchicine, the time-to-first event GPC showed a 12% lower proportional win rate compared with placebo (WR 0.88, 95% CI 0.79 to 0.98; win difference -2.10%, 95% CI -3.84 to -0.37), driven largely by excess diarrhoea. For spironolactone, patients experienced a 14% lower win rate (WR 0.86, 95% CI 0.75 to 0.99; win difference -1.46%, 95% CI -2.84% to -0.08%), largely attributable to gynaecomastia and hyperkalaemia. Conventional statistical approaches yielded concordant results. Across both interventions, higher-order efficacy outcomes (death, MI, stroke, heart failure) showed no benefit. CONCLUSIONS: In patients with post-MI, both low-dose colchicine and spironolactone demonstrated disadvantageous benefit-risk profiles, reinforcing that neither agent should be used routinely. This prespecified application of GPC provided results consistent with traditional methods but offered a clinically intuitive framework for interpreting composite outcomes.
引用
- d'Entremont, Jolly, Alharthi, et al. Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial. Heart. 2026. PMID: 40908114. doi:10.1136/heartjnl-2025-326218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。